Skip to content
The Policy VaultThe Policy Vault

Gilotrif (afatinib) — Highmark

metastatic NSCLC

Initial criteria

  • age ≥ 18 years
  • Diagnosis of metastatic NSCLC (ICD-10: C34) AND disease harbors EGFR exon 19 deletions OR EGFR exon 21 (L858R) substitution mutations OR non‑resistant EGFR mutation (S768I, L861Q, G719X)
  • OR diagnosis of squamous metastatic NSCLC AND disease has progressed on platinum‑based chemotherapy (e.g., carboplatin, oxaliplatin, etc.)